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Abstract
Mammography is an effective screening modality for the early detection of breast cancer.
The reduction in breast cancer mortality is greater for women aged over 50 at screening
than for women aged under 50. Mammography can also contribute to an understanding of
the biology of breast cancer. Screening trials provide good evidence for the dedifferentiation
of a cancer as it develops over time, and the age dependency of this dedifferentiation
explains much of the age difference in the effectiveness of screening. Mammographic
density is an important predictor of future breast cancer risk, and has potential as an early
endpoint in breast cancer prevention trials. Mammographic density is also an important
determinant of mammographic screening sensitivity.
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Introduction
The main interest in mammography has focused on its
value as a method of screening. However, the population-
screening trials conducted over the past 35 years have
generated extensive longitudinal data on the relation of
mammographic features both to tumour behaviour and the
future risk of breast cancer in the normal population. In this
review we briefly examine the effectiveness of mammo-
graphic screening, then discuss more generally the contri-
bution that mammography can make to understanding the
natural history and epidemiology of breast cancer.
The benefit of high-quality mammography
Mammography as a method of screening for the early detec-
tion of breast cancer has undergone many randomised trials.
The results of seven of the eight trials that have been pub-
lished display a considerable consistency. For women over
50 years of age at entry to a trial, the reduction in breast
cancer mortality in those invited to screening is approx. 25%,
and in women who are screened the reduction is approx.
33% [1]. For women under the age of 50 (the lower age limit
varies across the trials between 35 and 40 years), the reduc-
tion in breast cancer mortality is considerably less, approx.
15% in all women invited to screening [2]. The one dis-
crepant trial is the Canadian National Breast Screening. Two
aspects of this trial give cause for concern. Firstly, an inde-
pendent review of the quality of the mammography con-
cluded that, at least in the early stages, the quality was
unacceptably poor [3]. No one has ever suggested that poor
mammography is effective. Secondly, there was a substantial
and unexplained excess of advanced cancers at randomisa-
tion among women randomised to mammography, giving rise
to concern that the randomisation process might have been
poorly controlled [4,5].
The recent ‘overview’ in The Lancet
In view of the importance of breast screening to public
health, and the soundness of the evidence demonstrating
benefit, it was unfortunate that The Lancet chose to
publish an incompetent attempt at an overview [6]. TheBreast Cancer Research    Vol 2 No 4 Day and Warren
shortcomings of that paper are well described in an editorial
[7] and subsequent correspondence in The Lancet.
However, three points are worth noting. The first is that the
authors’ criticism of the randomisation process in most of
the Swedish trials is statistically incorrect because their
analysis ignores the cluster randomisation. The second is
that the difference in mean age between the trial arms in
some of the Swedish trials, which the authors used to dis-
credit the trials, are of negligible magnitude compared with
the observed effect on breast cancer mortality and are in
any case incorporated into the published analyses. The third
is the authors’ failure to acknowledge the serious inadequa-
cies of the Canadian Trial. The Gotsche–Olsen paper is an
example of uncritical application of arbitrary criteria, a trav-
esty of what overviews should be attempting to accomplish.
It is unfortunate that the name of the Cochrane Centre is
associated with it, because the value of the Cochrane
Centre depends heavily on the reliability of its output.
Mammographic screening, natural history of
breast cancer and the effect of age
Screening trials, in which one arm is regularly screened
and the other is left unscreened, provide perhaps the only
situation in which cancers arising in two identical popula-
tions differ only in the time of diagnosis. This permits the
examination of how breast cancers change as they evolve
with time. For this purpose one has to construct sets of
cancers that are comparable; this is achieved by consider-
ing incident cancers in the two arms of the trial, ie remov-
ing length bias by ignoring cancers detected at the initial
screening test for prevalence. As one would expect, inci-
dent breast cancers in the screening arm are smaller, and
a smaller proportion are node-positive. They also contain a
higher proportion of cancers classified histologically as
malignancy grade 1 and a lower proportion classified as
malignancy grade 3 [8]. These changes in size, nodal
status and malignancy grade seem in fact to be sufficient
to predict the effect of screening in breast cancer mortality
[9]; they can therefore be used both as early indicators of
the effectiveness of a screening programme and as surro-
gate endpoints of trials examining secondary aspects of
screening, such as changes in screening frequency [10].
Such an approach is being taken to evaluate the effect on
future breast cancer mortality of the UK national screening
programme, using the data from the East Anglia region.
This approach has the advantage that it is independent of
changes in treatment or in underlying cancer incidence,
both of which make the interpretation of changes in
observed breast cancer mortality problematic. This
approach has also been adopted in the UK trial of the
effect of changing the interscreening interval from 3 years
to 1 year. The use of predicted breast cancer mortality, on
the basis of the three prognostic factors, leads to trials
that are substantially smaller and shorter, for the same
power, than trials based on observed mortality.
The change in malignancy grade associated with diagno-
sis earlier in time, and at a smaller size, is clear evidence
that some cancers evolve as they grow. Given the hetero-
geneity of the cell population comprising a cancer, it is not
surprising that more malignant subclones evolve more
rapidly. With the use of screening trial data to model this
process of dedifferentiation and growth, it seems that the
process is age-dependent, with a transition to high-grade
malignancy occurring earlier in women under the age of
50. Mammography is also less sensitive at detecting small
cancers in younger women, owing to the greater mammo-
graphic density of breast tissues (described in the next
section). The effects of age on both sensitivity and the
process of dedifferentiation provide an elegant explanation
of the effect of age on the reduction in breast cancer mor-
tality attributable to screening [11].
Figures 1 and 2 show breast cancer mortality in the
Swedish two-county study by study arm, age and malig-
nancy grade. For women under the age of 50, mortality
due to grade 3 cancers is unaffected by screening, in con-
trast with women over age 50 for whom the effect is sub-
stantial and early, relative to the effect for lower-grade
cancers. For grade 2 cancers, the effect of screening on
mortality is not appreciably affected by age (Figures 3 and
4). A clear picture emerges: cancers with a high malig-
nancy grade have a poorer prognosis and lead to earlier
death than lower-grade cancers; in younger women, tran-
sition to high-grade malignancy occurs more often at a
smaller tumour size, and these smaller cancers are les s
readily detected at screening. The consequence is that
mammography in women under 50 makes little impact on
mortality due to high-grade cancers. The overall effect,
compared with that in women over 50, is both smaller in
magnitude and delayed in time.
Prognosis and mammographic features at
diagnosis
The survival of women with small invasive breast cancers
(less than 15 mm in diameter), often detected by mammog-
raphy, is usually good. In a series of 343 such cancers in
Sweden, survival after a median follow-up time of 6 years
was 93%. Mammograms at diagnosis were classified into
one of four categories: stellate (spiculated) mass with no
calcifications, circular or oval lesions with no calcifications,
spiculated or circular with non-casting-type calcifications,
and casting-type calcifications. Of the 24 deaths in the
343 women, 8 occurred in the 24 women with casting-type
calcifications at diagnosis. None of the 24 deaths occurred
in women who had node-positive cancers. The relative
hazard of mortality in those with casting-type calcifications
compared with the rest of the group was approximately
sixfold [12]. For those with small cancers, it seems that the
traditional prognostic factors of nodal status and malig-
nancy grade are of little value in differentiating risk. The
mammographic appearance is a better reflection of the bio-http://breast-cancer-research.com/content/2/4/247
logical characteristic of the cancer. This identification of a
high-risk group of small cancers should be of considerable
therapeutic importance.
Mammographic density and breast cancer risk
Since the early work of Wolfe [13] it has been known
that the mammographic density of breast tissue is
related to the risk of developing breast cancer. Fatty
breast tissue is relatively translucent, in contrast with
epithelial or stromal tissue. Classification estimates the
proportion of the total breast area that is occupied by
mammographically dense tissue. A four-point scale was
originally used, although some researchers have used
the numerical proportion [14]. On a four-point scale,
studies have reported relative risks of between 2 and 6
for the risk of the most dense category compared with
the least dense, with a smooth gradient across the cate-
gories. With values between 2 and 6, mammographic
density is a stronger risk factor, apart from age and
BRCA1 and BRCA2 mutations, than almost any other
risk factor studied [15].
Groups of women at all ages include individuals with
fatty, moderate density and dense patterns, but the pro-
portion of women with dense breasts decreases with
age, from over 70% for premenopausal women aged
40–49 to approx. 25% for women aged 65–69 [16]. If
we take a definition of dense breasts based on the pro-
portion of the breast area occupied by dense tissue, as
described above, the proportion of women with dense
Figure 1
Cumulative mortality from grade 3 ductal carcinoma, women 50–74,
invited to screening and control groups. RR, relative risk.
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Figure 2
Cumulative mortality from grade 3 ductal carcinoma, women 40–49,
invited to screening and control groups. RR, relative risk.
Figure 3
Cumulative mortality from grade 2 ductal carcinoma, women 50–74,
invited to screening and control groups. RR, relative risk.
0
20
40
60
80
100
120
140
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Control
Invited
Time in years since randomization to Dec 31 1994
RR 0.64 (0.30–1.41)
Figure 4
Cumulative mortality from grade 2 ductal carcinoma, women 40–49,
invited to screening and control groups. RR, relative risk.
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RR 0.64 (0.480.86)breasts decreases with increasing obesity because
there is more fat tissue. For the risk factors age and
obesity, the association with breast density goes con-
trary to the gradient of risk for breast cancer. To com-
pensate properly for the obesity effect it is possible that
a definition of breast density as an expression of the
total volume of dense breast tissue, rather than the
current definition based on area, might be more appro-
priate. For other risk factors, the association with breast
density follows the gradient of risk, seen most notably
for parity. Nulliparous and low parity women have a sub-
stantially greater probability of having dense breasts
than parous women (odds ratio of approximately 4) [17].
Similar trends are found for age at menopause and use
of hormone replacement therapy.
The effect of tamoxifen on breast density is consistent with
the decrease in breast cancer risk after the use of tamox-
ifen. After 12 months or more of tamoxifen use, the
decrease in the proportion of women with dense breasts is
quantitatively consistent with the reported reduction in
breast cancer risk [18]. Breast density therefore has poten-
tial as an early endpoint, quantitatively predictive of future
breast cancer risk, for trials of hormonal interventions.
The effects of mammographic density on
screening effectiveness
Breast density also has a major impact on breast screen-
ing. Dense tissue obscures the radiological picture and
makes the identification of cancers more difficult. The
result is a lower sensitivity and a higher rate of interval
cancers in relation to the screening detection rate and the
underlying incidence. Early results from the Swedish two-
county study reporting higher interval cancer rates in
women under 50, in comparison with older women, and a
smaller proportion of stage 1 cancers detected in those
screened, reflect this lower sensitivity [19].
More recent analyses of the UK national screening data
from East Anglia have demonstrated a particularly high pro-
portion of dense breasts among the interval cancers [20].
An additional finding was that dense breast tissue was
associated with cancers of malignancy grade 3. Thus,
interval cancers were found to be associated with both
high-density and grade 3 tumours. This might suggest that
the cancers missed owing to the breast density were of
high grade on account of their size. However, the associa-
tion of high density with grade 3 tumours seemed to
remain after controlling for tumour size and mode of detec-
tion. If confirmed in another series it would be an additional
indication that the mammographic pattern both of the
breast tissue and of breast cancers is a reflection of under-
lying biological processes. The association of density both
with higher cancer incidence (particularly of grade 3
cancers) and with lower screening sensitivity has implica-
tions for the organisation of screening programmes.
Improving sensitivity in high-density tissue should be a
prime focus of the programme’s continuing quality assur-
ance activity. In this regard, one can note that the benefit
of tamoxifen, or compounds with similar benefits but fewer
harmful side effects, not only would be to reduce breast
cancer incidence, but would also improve the sensitivity of
mammography in detecting the cancers that do appear.
Conclusion
The benefits of mammographic screening for women over
50 are well established. Effectiveness under this age is
more marginal. Breast screening programmes and the
radiological images generated by mammography provide
their own contribution to the understanding of tumour
biology. The mammographic features of tumours and of
normal breast tissue are probably an underused resource
in breast cancer research.
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